ID   LAT1_HUMAN              Reviewed;         507 AA.
AC   Q01650; Q8IV97; Q9UBN8; Q9UP15; Q9UQC0;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2001, sequence version 2.
DT   10-MAY-2017, entry version 177.
DE   RecName: Full=Large neutral amino acids transporter small subunit 1;
DE   AltName: Full=4F2 light chain;
DE            Short=4F2 LC;
DE            Short=4F2LC;
DE   AltName: Full=CD98 light chain;
DE   AltName: Full=Integral membrane protein E16;
DE   AltName: Full=L-type amino acid transporter 1;
DE            Short=hLAT1;
DE   AltName: Full=Solute carrier family 7 member 5;
DE   AltName: Full=y+ system cationic amino acid transporter;
GN   Name=SLC7A5; Synonyms=CD98LC, LAT1, MPE16;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBUNIT, AND VARIANT LYS-230.
RX   PubMed=9751058; DOI=10.1038/26246;
RA   Mastroberardino L., Spindler B., Pfeiffer R., Skelly P.J., Loffing J.,
RA   Shoemaker C.B., Verrey F.;
RT   "Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a
RT   permease family.";
RL   Nature 395:288-291(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBUNIT, AND TISSUE SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=10049700; DOI=10.1006/bbrc.1999.0206;
RA   Prasad P.D., Wang H., Huang W., Kekuda R., Rajan D.P., Leibach F.H.,
RA   Ganapathy V.;
RT   "Human LAT1, a subunit of system L amino acid transporter: molecular
RT   cloning and transport function.";
RL   Biochem. Biophys. Res. Commun. 255:283-288(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=10072483;
RA   Tsurudome M., Ito M., Takebayashi S., Okumura K., Nishio M.,
RA   Kawano M., Kusagawa S., Komada H., Ito Y.;
RT   "Primary structure of the light chain of fusion regulatory protein-
RT   1/CD98/4F2 predicts a protein with multiple transmembrane domains that
RT   is almost identical to the amino acid transporter E16.";
RL   J. Immunol. 162:2462-2466(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBUNIT, AND TISSUE SPECIFICITY.
RC   TISSUE=Ovary;
RX   PubMed=11557028; DOI=10.1016/S0005-2736(01)00384-4;
RA   Yanagida O., Kanai Y., Chairoungdua A., Kim D.K., Segawa H., Nii T.,
RA   Cha S.H., Matsuo H., Fukushima J., Fukasawa Y., Tani Y., Taketani Y.,
RA   Uchino H., Kim J.Y., Inatomi J., Okayasu I., Miyamoto K., Takeda E.,
RA   Goya T., Endou H.;
RT   "Human L-type amino acid transporter 1 (LAT1): characterization of
RT   function and expression in tumor cell lines.";
RL   Biochim. Biophys. Acta 1514:291-302(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Minato N., Iwai K., Takizawa C., Nakamura E.;
RT   "Human 4F2 light chain: amino acid transporter.";
RL   Submitted (SEP-1998) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-223.
RC   TISSUE=Liver, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 181-507, TISSUE SPECIFICITY, AND
RP   INDUCTION.
RC   TISSUE=Peripheral blood lymphocyte;
RX   PubMed=1597461;
RA   Gaugitsch H.W., Prieschl E.E., Kalthoff F., Huber N.E., Baumruker T.;
RT   "A novel transiently expressed, integral membrane protein linked to
RT   cell activation. Molecular cloning via the rapid degradation signal
RT   AUUUA.";
RL   J. Biol. Chem. 267:11267-11273(1992).
RN   [8]
RP   FUNCTION, AND INHIBITION.
RX   PubMed=10391915; DOI=10.1074/jbc.274.28.19738;
RA   Pineda M., Fernandez E., Torrents D., Estevez R., Lopez C., Camps M.,
RA   Lloberas J., Zorzano A., Palacin M.;
RT   "Identification of a membrane protein, LAT-2, that co-expresses with
RT   4F2 heavy chain, an L-type amino acid transport activity with broad
RT   specificity for small and large zwitterionic amino acids.";
RL   J. Biol. Chem. 274:19738-19744(1999).
RN   [9]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10574970; DOI=10.1074/jbc.274.49.34948;
RA   Rossier G., Meier C., Bauch C., Summa V., Sordat B., Verrey F.,
RA   Kuehn L.C.;
RT   "LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter
RT   of kidney and intestine.";
RL   J. Biol. Chem. 274:34948-34954(1999).
RN   [10]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=11311135;
RA   Broeer A., Friedrich B., Wagner C.A., Fillon S., Ganapathy V.,
RA   Lang F., Broeer S.;
RT   "Association of 4F2hc with light chains LAT1, LAT2 or y+LAT2 requires
RT   different domains.";
RL   Biochem. J. 355:725-731(2001).
RN   [11]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   INHIBITION.
RX   PubMed=11389679; DOI=10.1042/0264-6021:3560719;
RA   Ritchie J.W.A., Taylor P.M.;
RT   "Role of the System L permease LAT1 in amino acid and iodothyronine
RT   transport in placenta.";
RL   Biochem. J. 356:719-725(2001).
RN   [12]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND INHIBITION.
RX   PubMed=11564694; DOI=10.1210/endo.142.10.8418;
RA   Friesema E.C.H., Docter R., Moerings E.P.C.M., Verrey F.,
RA   Krenning E.P., Hennemann G., Visser T.J.;
RT   "Thyroid hormone transport by the heterodimeric human system L amino
RT   acid transporter.";
RL   Endocrinology 142:4339-4348(2001).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=11742812;
RA   Okamoto Y., Sakata M., Ogura K., Yamamoto T., Yamaguchi M., Tasaka K.,
RA   Kurachi H., Tsurudome M., Murata Y.;
RT   "Expression and regulation of 4F2hc and hLAT1 in human trophoblasts.";
RL   Am. J. Physiol. 282:C196-C204(2002).
RN   [14]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND INHIBITION.
RX   PubMed=12117417; DOI=10.1042/BJ20020841;
RA   Simmons-Willis T.A., Koh A.S., Clarkson T.W., Ballatori N.;
RT   "Transport of a neurotoxicant by molecular mimicry: the methylmercury-
RT   L-cysteine complex is a substrate for human L-type large neutral amino
RT   acid transporter (LAT) 1 and LAT2.";
RL   Biochem. J. 367:239-246(2002).
RN   [15]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, SUBCELLULAR
RP   LOCATION, AND INHIBITION.
RX   PubMed=12225859; DOI=10.1016/S0005-2736(02)00516-3;
RA   Kim D.K., Kanai Y., Choi H.W., Tangtrongsup S., Chairoungdua A.,
RA   Babu E., Tachampa K., Anzai N., Iribe Y., Endou H.;
RT   "Characterization of the system L amino acid transporter in T24 human
RT   bladder carcinoma cells.";
RL   Biochim. Biophys. Acta 1565:112-121(2002).
RN   [16]
RP   TISSUE SPECIFICITY.
RX   PubMed=12824232; DOI=10.1167/iovs.02-0907;
RA   Jain-Vakkalagadda B., Dey S., Pal D., Mitra A.K.;
RT   "Identification and functional characterization of a Na+-independent
RT   large neutral amino acid transporter, LAT1, in human and rabbit
RT   cornea.";
RL   Invest. Ophthalmol. Vis. Sci. 44:2919-2927(2003).
RN   [17]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=16027961; DOI=10.1007/s00726-005-0221-x;
RA   Fraga S., Pinho M.J., Soares-da-Silva P.;
RT   "Expression of LAT1 and LAT2 amino acid transporters in human and rat
RT   intestinal epithelial cells.";
RL   Amino Acids 29:229-233(2005).
RN   [18]
RP   FUNCTION, SUBUNIT, AND INHIBITION.
RX   PubMed=15769744; DOI=10.1074/jbc.M413164200;
RA   Li S., Whorton A.R.;
RT   "Identification of stereoselective transporters for S-nitroso-L-
RT   cysteine: role of LAT1 and LAT2 in biological activity of S-
RT   nitrosothiols.";
RL   J. Biol. Chem. 280:20102-20110(2005).
RN   [19]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=16496379; DOI=10.1002/ijc.21866;
RA   Nawashiro H., Otani N., Shinomiya N., Fukui S., Ooigawa H., Shima K.,
RA   Matsuo H., Kanai Y., Endou H.;
RT   "L-type amino acid transporter 1 as a potential molecular target in
RT   human astrocytic tumors.";
RL   Int. J. Cancer 119:484-492(2006).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [21]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND INHIBITION.
RX   PubMed=18262359; DOI=10.1016/j.neulet.2008.01.028;
RA   Vumma R., Wiesel F.A., Flyckt L., Bjerkenstedt L., Venizelos N.;
RT   "Functional characterization of tyrosine transport in fibroblast cells
RT   from healthy controls.";
RL   Neurosci. Lett. 434:56-60(2008).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31 AND THR-45, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31; SER-35 AND THR-45,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- FUNCTION: Sodium-independent, high-affinity transport of large
CC       neutral amino acids such as phenylalanine, tyrosine, leucine,
CC       arginine and tryptophan, when associated with SLC3A2/4F2hc.
CC       Involved in cellular amino acid uptake. Acts as an amino acid
CC       exchanger. Involved in the transport of L-DOPA across the blood-
CC       brain barrier, and that of thyroid hormones triiodothyronine (T3)
CC       and thyroxine (T4) across the cell membrane in tissues such as
CC       placenta. Plays a role in neuronal cell proliferation
CC       (neurogenesis) in brain. Involved in the uptake of methylmercury
CC       (MeHg) when administered as the L-cysteine or D,L-homocysteine
CC       complexes, and hence plays a role in metal ion homeostasis and
CC       toxicity. Involved in the cellular activity of small molecular
CC       weight nitrosothiols, via the stereoselective transport of L-
CC       nitrosocysteine (L-CNSO) across the transmembrane. May play an
CC       important role in high-grade gliomas. Mediates blood-to-retina L-
CC       leucine transport across the inner blood-retinal barrier which in
CC       turn may play a key role in maintaining large neutral amino acids
CC       as well as neurotransmitters in the neural retina. Acts as the
CC       major transporter of tyrosine in fibroblasts.
CC       {ECO:0000269|PubMed:10049700, ECO:0000269|PubMed:10391915,
CC       ECO:0000269|PubMed:10574970, ECO:0000269|PubMed:11311135,
CC       ECO:0000269|PubMed:11389679, ECO:0000269|PubMed:11557028,
CC       ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:11742812,
CC       ECO:0000269|PubMed:12117417, ECO:0000269|PubMed:12225859,
CC       ECO:0000269|PubMed:15769744, ECO:0000269|PubMed:16496379,
CC       ECO:0000269|PubMed:18262359, ECO:0000269|PubMed:9751058}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=7.9 uM for T4 (in the presence of choline chloride)
CC         {ECO:0000269|PubMed:10574970, ECO:0000269|PubMed:11564694,
CC         ECO:0000269|PubMed:12117417, ECO:0000269|PubMed:12225859,
CC         ECO:0000269|PubMed:18262359};
CC         KM=0.8 uM for T3 (in the presence of choline chloride)
CC         {ECO:0000269|PubMed:10574970, ECO:0000269|PubMed:11564694,
CC         ECO:0000269|PubMed:12117417, ECO:0000269|PubMed:12225859,
CC         ECO:0000269|PubMed:18262359};
CC         KM=12.5 uM for reverse triiodothyronine (rT3) (in the presence
CC         of choline chloride) {ECO:0000269|PubMed:10574970,
CC         ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:12117417,
CC         ECO:0000269|PubMed:12225859, ECO:0000269|PubMed:18262359};
CC         KM=7.9 uM for 3,3'-diiodothyronine (in the presence of choline
CC         chloride) {ECO:0000269|PubMed:10574970,
CC         ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:12117417,
CC         ECO:0000269|PubMed:12225859, ECO:0000269|PubMed:18262359};
CC         KM=46 uM for leucine (in the presence of choline chloride)
CC         {ECO:0000269|PubMed:10574970, ECO:0000269|PubMed:11564694,
CC         ECO:0000269|PubMed:12117417, ECO:0000269|PubMed:12225859,
CC         ECO:0000269|PubMed:18262359};
CC         KM=19 uM for tryptophan (in the presence of choline chloride)
CC         {ECO:0000269|PubMed:10574970, ECO:0000269|PubMed:11564694,
CC         ECO:0000269|PubMed:12117417, ECO:0000269|PubMed:12225859,
CC         ECO:0000269|PubMed:18262359};
CC         KM=32 uM for L-leucine {ECO:0000269|PubMed:10574970,
CC         ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:12117417,
CC         ECO:0000269|PubMed:12225859, ECO:0000269|PubMed:18262359};
CC         KM=10 mM for L-alanine {ECO:0000269|PubMed:10574970,
CC         ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:12117417,
CC         ECO:0000269|PubMed:12225859, ECO:0000269|PubMed:18262359};
CC         KM=2.2 mM for L-glutamine {ECO:0000269|PubMed:10574970,
CC         ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:12117417,
CC         ECO:0000269|PubMed:12225859, ECO:0000269|PubMed:18262359};
CC         KM=35 uM for L-histidine {ECO:0000269|PubMed:10574970,
CC         ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:12117417,
CC         ECO:0000269|PubMed:12225859, ECO:0000269|PubMed:18262359};
CC         KM=740 uM for L-phenylalanine {ECO:0000269|PubMed:10574970,
CC         ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:12117417,
CC         ECO:0000269|PubMed:12225859, ECO:0000269|PubMed:18262359};
CC         KM=98 uM for MeHg-L-cysteine {ECO:0000269|PubMed:10574970,
CC         ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:12117417,
CC         ECO:0000269|PubMed:12225859, ECO:0000269|PubMed:18262359};
CC         KM=99 uM for methionine {ECO:0000269|PubMed:10574970,
CC         ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:12117417,
CC         ECO:0000269|PubMed:12225859, ECO:0000269|PubMed:18262359};
CC         KM=55.2 uM for phenylalanine (in T24 human bladder carcinoma
CC         cells) {ECO:0000269|PubMed:10574970,
CC         ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:12117417,
CC         ECO:0000269|PubMed:12225859, ECO:0000269|PubMed:18262359};
CC         KM=60.4 uM for tyrosine (in T24 human bladder carcinoma cells)
CC         {ECO:0000269|PubMed:10574970, ECO:0000269|PubMed:11564694,
CC         ECO:0000269|PubMed:12117417, ECO:0000269|PubMed:12225859,
CC         ECO:0000269|PubMed:18262359};
CC         KM=16.4 uM for tyrosine (in human fibroblasts)
CC         {ECO:0000269|PubMed:10574970, ECO:0000269|PubMed:11564694,
CC         ECO:0000269|PubMed:12117417, ECO:0000269|PubMed:12225859,
CC         ECO:0000269|PubMed:18262359};
CC         KM=138 uM for Dopa (in T24 human bladder carcinoma cells)
CC         {ECO:0000269|PubMed:10574970, ECO:0000269|PubMed:11564694,
CC         ECO:0000269|PubMed:12117417, ECO:0000269|PubMed:12225859,
CC         ECO:0000269|PubMed:18262359};
CC         KM=96.5 uM for 3-O-methyldopa (in T24 human bladder carcinoma
CC         cells) {ECO:0000269|PubMed:10574970,
CC         ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:12117417,
CC         ECO:0000269|PubMed:12225859, ECO:0000269|PubMed:18262359};
CC         KM=153 uM for alpha-methyltyrosine (in T24 human bladder
CC         carcinoma cells) {ECO:0000269|PubMed:10574970,
CC         ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:12117417,
CC         ECO:0000269|PubMed:12225859, ECO:0000269|PubMed:18262359};
CC         KM=216 uM for alpha-methyldopa (in T24 human bladder carcinoma
CC         cells) {ECO:0000269|PubMed:10574970,
CC         ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:12117417,
CC         ECO:0000269|PubMed:12225859, ECO:0000269|PubMed:18262359};
CC         KM=191 uM for gabapentin (in T24 human bladder carcinoma cells)
CC         {ECO:0000269|PubMed:10574970, ECO:0000269|PubMed:11564694,
CC         ECO:0000269|PubMed:12117417, ECO:0000269|PubMed:12225859,
CC         ECO:0000269|PubMed:18262359};
CC         KM=7.3 uM for triiodothyronine (in T24 human bladder carcinoma
CC         cells) {ECO:0000269|PubMed:10574970,
CC         ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:12117417,
CC         ECO:0000269|PubMed:12225859, ECO:0000269|PubMed:18262359};
CC         KM=162 uM for thyroxine (in T24 human bladder carcinoma cells)
CC         {ECO:0000269|PubMed:10574970, ECO:0000269|PubMed:11564694,
CC         ECO:0000269|PubMed:12117417, ECO:0000269|PubMed:12225859,
CC         ECO:0000269|PubMed:18262359};
CC         KM=75.3 uM for melphanan (in T24 human bladder carcinoma cells)
CC         {ECO:0000269|PubMed:10574970, ECO:0000269|PubMed:11564694,
CC         ECO:0000269|PubMed:12117417, ECO:0000269|PubMed:12225859,
CC         ECO:0000269|PubMed:18262359};
CC         KM=156 uM for BCH (in T24 human bladder carcinoma cells)
CC         {ECO:0000269|PubMed:10574970, ECO:0000269|PubMed:11564694,
CC         ECO:0000269|PubMed:12117417, ECO:0000269|PubMed:12225859,
CC         ECO:0000269|PubMed:18262359};
CC   -!- SUBUNIT: Disulfide-linked heterodimer with the amino acid
CC       transport protein SLC3A2/4F2hc. {ECO:0000269|PubMed:10049700,
CC       ECO:0000269|PubMed:11311135, ECO:0000269|PubMed:11389679,
CC       ECO:0000269|PubMed:11557028, ECO:0000269|PubMed:11564694,
CC       ECO:0000269|PubMed:12225859, ECO:0000269|PubMed:15769744,
CC       ECO:0000269|PubMed:9751058}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Apical cell membrane;
CC       Multi-pass membrane protein. Note=Located to the plasma membrane
CC       by SLC3A2/4F2hc. Localized to the apical membrane of placental
CC       syncytiophoblastic cells. Expressed in both luminal and abluminal
CC       membranes of brain capillary endothelial cells (By similarity).
CC       {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed abundantly in adult lung, liver,
CC       brain, skeletal muscle, placenta, bone marrow, testis, resting
CC       lymphocytes and monocytes, and in fetal liver. Weaker expression
CC       in thymus, cornea, retina, peripheral leukocytes, spleen, kidney,
CC       colon and lymph node. During gestation, expression in the placenta
CC       was significantly stronger at full-term than at the mid-trimester
CC       stage. Also expressed in all human tumor cell lines tested and in
CC       the astrocytic process of primary astrocytic gliomas. Expressed in
CC       retinal endothelial cells and in the intestinal epithelial cell
CC       line Caco-2. {ECO:0000269|PubMed:10049700,
CC       ECO:0000269|PubMed:10072483, ECO:0000269|PubMed:11389679,
CC       ECO:0000269|PubMed:11557028, ECO:0000269|PubMed:11742812,
CC       ECO:0000269|PubMed:12824232, ECO:0000269|PubMed:1597461,
CC       ECO:0000269|PubMed:16027961, ECO:0000269|PubMed:16496379}.
CC   -!- INDUCTION: Expression induced in quiescent peripheral blood
CC       lymphocytes after treatment with phorbol myristate acetate (PMA)
CC       and phytohemagglutinin (PHA). Expression and the uptake of leucine
CC       is stimulated in mononuclear, cytotrophoblast-like choriocarcinoma
CC       cells by combined treatment with PMA and calcium ionophore.
CC       {ECO:0000269|PubMed:11742812, ECO:0000269|PubMed:1597461}.
CC   -!- MISCELLANEOUS: The uptake of leucine, tyrosine and tryptophan is
CC       inhibited by the different iodothyronines, in particular T3.
CC       Leucine transport is also inhibited by small zwitterionic amino
CC       acids (i.e. glycine, alanine, serine, threonine and cysteine) and
CC       by glutamine and asparginine. The uptake of T3 is almost
CC       completely blocked by coincubation with leucine, tryptophan,
CC       tyrosine, and phenylalanine, or 2-amino-bicyclo-(2,2,1)-heptane-2-
CC       carboxylate (BCH). Methionine uptake was inhibited by the L-system
CC       substrates L-leucine, BCH, L-cysteine and by the MeHg-L-cysteine
CC       complex and structurally related S-ethyl-L-cysteine. MeHg-L-
CC       cysteine uptake is inhibited by L-methionine, L-leucine, BCH and
CC       S-ethyl-L-cysteine. L-leucine uptake was inhibited by L-CNSO.
CC       Tyrosine uptake in fibroblasts was inhibited by D-methionine, and
CC       methyl-aminoisobutyric acid (MeAIB).
CC   -!- SIMILARITY: Belongs to the amino acid-polyamine-organocation (APC)
CC       superfamily. L-type amino acid transporter (LAT) (TC 2.A.3.8)
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF077866; AAC61479.1; -; mRNA.
DR   EMBL; AF104032; AAD20464.1; -; mRNA.
DR   EMBL; AB018542; BAA33851.1; -; mRNA.
DR   EMBL; AB018009; BAA84648.1; -; mRNA.
DR   EMBL; AB017908; BAA75746.1; -; mRNA.
DR   EMBL; BC039692; AAH39692.1; -; mRNA.
DR   EMBL; BC042600; AAH42600.1; -; mRNA.
DR   EMBL; M80244; AAA35780.1; -; mRNA.
DR   CCDS; CCDS10964.1; -.
DR   PIR; JG0165; JG0165.
DR   RefSeq; NP_003477.4; NM_003486.6.
DR   UniGene; Hs.513797; -.
DR   ProteinModelPortal; Q01650; -.
DR   BioGrid; 113801; 15.
DR   IntAct; Q01650; 19.
DR   MINT; MINT-5000558; -.
DR   STRING; 9606.ENSP00000261622; -.
DR   ChEMBL; CHEMBL4459; -.
DR   DrugBank; DB01746; D-Leucine.
DR   DrugBank; DB02556; D-Phenylalanine.
DR   DrugBank; DB00509; Dextrothyroxine.
DR   DrugBank; DB01235; Levodopa.
DR   DrugBank; DB00451; Levothyroxine.
DR   DrugBank; DB00279; Liothyronine.
DR   DrugBank; DB01042; Melphalan.
DR   DrugBank; DB02750; S-(Methylmercury)-L-Cysteine.
DR   TCDB; 2.A.3.8.25; the amino acid-polyamine-organocation (apc) family.
DR   iPTMnet; Q01650; -.
DR   PhosphoSitePlus; Q01650; -.
DR   SwissPalm; Q01650; -.
DR   BioMuta; SLC7A5; -.
DR   DMDM; 12643412; -.
DR   EPD; Q01650; -.
DR   MaxQB; Q01650; -.
DR   PaxDb; Q01650; -.
DR   PeptideAtlas; Q01650; -.
DR   PRIDE; Q01650; -.
DR   TopDownProteomics; Q01650; -.
DR   DNASU; 8140; -.
DR   Ensembl; ENST00000261622; ENSP00000261622; ENSG00000103257.
DR   GeneID; 8140; -.
DR   KEGG; hsa:8140; -.
DR   UCSC; uc002fkm.4; human.
DR   CTD; 8140; -.
DR   DisGeNET; 8140; -.
DR   GeneCards; SLC7A5; -.
DR   HGNC; HGNC:11063; SLC7A5.
DR   HPA; HPA052673; -.
DR   HPA; HPA056077; -.
DR   MIM; 600182; gene.
DR   neXtProt; NX_Q01650; -.
DR   OpenTargets; ENSG00000103257; -.
DR   PharmGKB; PA35923; -.
DR   eggNOG; KOG1287; Eukaryota.
DR   eggNOG; COG0531; LUCA.
DR   GeneTree; ENSGT00760000119037; -.
DR   HOGENOM; HOG000098892; -.
DR   HOVERGEN; HBG000476; -.
DR   InParanoid; Q01650; -.
DR   KO; K13780; -.
DR   OMA; MIWLRHR; -.
DR   OrthoDB; EOG091G07EM; -.
DR   PhylomeDB; Q01650; -.
DR   TreeFam; TF313355; -.
DR   BioCyc; MetaCyc:ENSG00000103257-MONOMER; -.
DR   Reactome; R-HSA-210991; Basigin interactions.
DR   Reactome; R-HSA-352230; Amino acid transport across the plasma membrane.
DR   Reactome; R-HSA-71240; Tryptophan catabolism.
DR   SABIO-RK; Q01650; -.
DR   ChiTaRS; SLC7A5; human.
DR   GeneWiki; SLC7A5; -.
DR   GenomeRNAi; 8140; -.
DR   PRO; PR:Q01650; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000103257; -.
DR   CleanEx; HS_SLC7A5; -.
DR   ExpressionAtlas; Q01650; baseline and differential.
DR   Genevisible; Q01650; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0015171; F:amino acid transmembrane transporter activity; ISS:UniProtKB.
DR   GO; GO:0015297; F:antiporter activity; IBA:GO_Central.
DR   GO; GO:0015179; F:L-amino acid transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0015175; F:neutral amino acid transmembrane transporter activity; TAS:ProtInc.
DR   GO; GO:0042605; F:peptide antigen binding; ISS:UniProtKB.
DR   GO; GO:0006865; P:amino acid transport; TAS:Reactome.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0006520; P:cellular amino acid metabolic process; TAS:ProtInc.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0007399; P:nervous system development; IEA:UniProtKB-KW.
DR   GO; GO:0015804; P:neutral amino acid transport; ISS:UniProtKB.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   GO; GO:0006569; P:tryptophan catabolic process; TAS:Reactome.
DR   InterPro; IPR002293; AA/rel_permease1.
DR   InterPro; IPR004760; L_AA_transporter.
DR   Pfam; PF13520; AA_permease_2; 1.
DR   PIRSF; PIRSF006060; AA_transporter; 1.
DR   TIGRFAMs; TIGR00911; 2A0308; 1.
PE   1: Evidence at protein level;
KW   Amino-acid transport; Cell membrane; Complete proteome; Cytoplasm;
KW   Developmental protein; Differentiation; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Isopeptide bond; Membrane; Neurogenesis;
KW   Phosphoprotein; Polymorphism; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport; Ubl conjugation.
FT   CHAIN         1    507       Large neutral amino acids transporter
FT                                small subunit 1.
FT                                /FTId=PRO_0000054270.
FT   TRANSMEM     50     70       Helical. {ECO:0000255}.
FT   TRANSMEM     84    104       Helical. {ECO:0000255}.
FT   TRANSMEM    120    140       Helical. {ECO:0000255}.
FT   TRANSMEM    146    166       Helical. {ECO:0000255}.
FT   TRANSMEM    170    190       Helical. {ECO:0000255}.
FT   TRANSMEM    199    219       Helical. {ECO:0000255}.
FT   TRANSMEM    243    263       Helical. {ECO:0000255}.
FT   TRANSMEM    274    294       Helical. {ECO:0000255}.
FT   TRANSMEM    319    339       Helical. {ECO:0000255}.
FT   TRANSMEM    396    416       Helical. {ECO:0000255}.
FT   TRANSMEM    431    451       Helical. {ECO:0000255}.
FT   TRANSMEM    458    478       Helical. {ECO:0000255}.
FT   MOD_RES      31     31       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      35     35       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      45     45       Phosphothreonine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   CARBOHYD     49     49       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    230    230       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    340    340       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CROSSLNK     19     19       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   CROSSLNK     30     30       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   VARIANT     223    223       D -> V (in dbSNP:rs17853937).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_070119.
FT   VARIANT     230    230       N -> K (in dbSNP:rs1060250).
FT                                {ECO:0000269|PubMed:9751058}.
FT                                /FTId=VAR_048157.
FT   CONFLICT     15     15       A -> V (in Ref. 5; BAA75746).
FT                                {ECO:0000305}.
FT   CONFLICT     29     31       AKS -> SKR (in Ref. 5; BAA75746).
FT                                {ECO:0000305}.
FT   CONFLICT     35     35       S -> A (in Ref. 5; BAA75746).
FT                                {ECO:0000305}.
FT   CONFLICT     62     62       T -> A (in Ref. 5; BAA75746).
FT                                {ECO:0000305}.
FT   CONFLICT     88     88       V -> M (in Ref. 5; BAA75746).
FT                                {ECO:0000305}.
FT   CONFLICT    154    154       T -> A (in Ref. 5; BAA75746).
FT                                {ECO:0000305}.
SQ   SEQUENCE   507 AA;  55010 MW;  767F3C60B62C0F02 CRC64;
     MAGAGPKRRA LAAPAAEEKE EAREKMLAAK SADGSAPAGE GEGVTLQRNI TLLNGVAIIV
     GTIIGSGIFV TPTGVLKEAG SPGLALVVWA ACGVFSIVGA LCYAELGTTI SKSGGDYAYM
     LEVYGSLPAF LKLWIELLII RPSSQYIVAL VFATYLLKPL FPTCPVPEEA AKLVACLCVL
     LLTAVNCYSV KAATRVQDAF AAAKLLALAL IILLGFVQIG KGDVSNLDPN FSFEGTKLDV
     GNIVLALYSG LFAYGGWNYL NFVTEEMINP YRNLPLAIII SLPIVTLVYV LTNLAYFTTL
     STEQMLSSEA VAVDFGNYHL GVMSWIIPVF VGLSCFGSVN GSLFTSSRLF FVGSREGHLP
     SILSMIHPQL LTPVPSLVFT CVMTLLYAFS KDIFSVINFF SFFNWLCVAL AIIGMIWLRH
     RKPELERPIK VNLALPVFFI LACLFLIAVS FWKTPVECGI GFTIILSGLP VYFFGVWWKN
     KPKWLLQGIF STTVLCQKLM QVVPQET
//
